Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia

Atherosclerosis

Volumn 177, Issue 1, 2004, Pages 137-145

  Cohn, Jeffrey S ^a   Tremblay, Michel ^a   Batal, Rami ^a   Jacques, Hélne ^a   Rodriguez, Claudia ^a   Steiner, George ^b   Mamer, Orval ^c   Davignon, Jean ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Atherosclerosis; CAD; Kinetics; Mixed hyperlipidemia; Stable isotope; Triglyceride; Type III hyperlipoproteinemia; Very low density lipoprotein

Indexed keywords

APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN; INSULIN; LEUCINE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG INFUSION; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; KINETICS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, VLDL; MIDDLE AGED;

EID: 5444267382     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.06.011     Document Type: Article

References (50)

1. W.P. Castelli The triglyceride issue: a view from Framingham Am. Heart J. 112 1986 432 437
2. M.A. Austin Plasma triglyceride and coronary artery disease Arterioscler. Thromb. 11 1991 2 14
3. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein and Coronary Heart Disease. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993;269:505-10.
4. S.M. Grundy, and G.L. Vega Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment Arch. Int. Med. 152 1992 28 34
5. A.M. Gotto Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease Am. Heart J. 144 2002 33 42
6. J.C. Fruchart, and P. Duriez HDL and triglyceride as therapeutic targets Curr. Opin. Lipidol. 13 2002 605 616
7. M.C. Jong, M.H. Hofker, and L.M. Havekes Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3 Arterioscler. Thromb. Vasc. Biol. 19 1999 472 484
8. N.S. Shachter Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism Curr. Opin. Lipidol. 12 2001 297 304
9. H.B. Brewer Jr., R. Shulman, P. Herbert, R. Ronan, and K. Wehrly The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins J. Biol. Chem. 249 1974 4975 4984
10. C. Lenich, P. Brecher, S. Makrides, A. Chobanian, and V.I. Zannis Apolipoprotein gene expression in the rabbit: abundance, size, and distribution of apolipoprotein mRNA species in different tissues J. Lipid Res. 29 1988 755 764
11. G. Schonfeld, P.K. George, J. Miller, P. Reilly, and J. Witztum Apolipoprotein C-II and C-III levels in hyperlipoproteinemia Metabolism 28 1979 1001 1010
12. M.D. Curry, W.J. McConathy, J.D. Fesmire, and P. Alaupovic Quantitative determination of human apolipoprotein C-III by electroimmunoassay Biochem. Biophys. Acta 617 1980 503 513
13. M.L. Kashyap, L.S. Srivasta, B.A. Hynd, P.S. Gartside, and G. Perisutti Quantitation of human apolipoprotein C-III and its subspecies by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia J. Lipid Res. 22 1981 800 810
14. A. Fredenrich, L-M. Giroux, M. Tremblay, L. Krimbou, J. Davignon, and J.S. Cohn Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions J. Lipid Res. 38 1997 1421 1432
15. M. Dammerman, L.A. Sandkuijl, J.L. Halaas, W. Chung, and J.L. Breslow An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms Proc. Natl. Acad. Sci. U.S.A. 90 1993 4562 4566
16. A.P. Surguchov, G.P. Page, L. Smith, W. Patsch, and E. Boerwinkle Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia Arterioscler. Thromb. Vasc. Biol. 16 1996 941 947
17. J. Ribalta, A.E. La Ville, J.C. Vallvé, S. Humphries, P.R. Turner, and L. Masana A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia J. Lipid Res. 38 1997 1061 1069
18. T.M. Forte, A.V. Nichols, R.M. Krauss, and R.A. Norum Familial apolipoprotein AI and apolipoprotein C-III deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis J. Clin. Invest. 74 1984 1601 1613
19. A. Von Eckardstein, H. Holz, M. Sandkamp, W. Weng, H. Funke, and G. Assmann Apolipoprotein C-III (Lys58mGlu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia J. Clin. Invest. 87 1991 1724 1731
20. Y. Ito, N. Azrolan, A. O'Connell, A. Walsh, and J.L. Breslow Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice Science (Washington, DC) 249 1990 790 793
21. K. Aalto-Setala, E.A. Fisher, and X. Chen Mechanism of hypertriglyceridemia in human apolipoprotein (apo) C-III transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo C-III and reduced apo E on the particles J. Clin. Invest. 90 1992 1889 1900
22. H.V. de Silva, S.J. Lauer, and J. Wang Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E J. Biol. Chem. 269 1994 2324 2335
23. N. Maeda, H. Li, D. Lee, P. Oliver, S.H. Quarfordt, and J. Osada Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia J. Biol. Chem. 269 1994 10 16
24. W.V. Brown, and M.L. Baginsky Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein Biochem. Biophys. Res. Commun. 46 1972 375 382
25. R.M. Krauss, P.N. Herbert, R.I. Levy, and D.S. Fredrickson Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins Circ. Res. 33 1973 403 411
26. R.J. Havel, C.J. Fielding, T. Olivecrona, V.G. Shore, P.E. Fielding, and T. Egelrud Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources Biochemistry 12 1973 1828 1833
27. B.A. Landis, F.S. Rotolo, W.C. Meyers, A.B. Clark, and S.H. Quarfordt Influence of apolipoprotein E on soluble and heparin-immobilized hepatic lipase Am. J. Physiol. 252 1987 G805 810
28. H.H.J.J. Van Barlingen, H. de Jong, D.W. Erkelens, and T.W.A. de Bruin Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C J. Lipid Res. 37 1996 754 763
29. E. Windler, and R.J. Havel Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver J. Lipid Res. 26 1985 556 563
30. V. Clavey, S. Lestavel-Delattre, C. Copin, J.M. Bard, and J.C. Fruchart Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII CIII and E Arterioscler. Thromb. Vasc. Biol. 15 1995 963 971
31. C.J. Mann, A.A. Troussard, and F.T. Yen Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor J. Biol. Chem. 272 1997 48 354
32. T. Ebara, R. Ramakrishnan, G. Steiner, and N.S. Shachter Chylomicronemia due to apolipoprotein C III overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E J. Clin. Invest. 99 1997 2672 2681
33. M.W. Huff, N.H. Fidge, P.J. Nestel, T. Billington, and B. Watson Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects J. Lipid Res. 22 1981 1235 1246
34. M.W. Huff, and P.J. Nestel Metabolism of apolipoproteins CII, CI II1, CIII2 and VLDL-B in human subjects consuming high carbohydrate diets Metabolism 31 1982 493 498
35. C.L. Malmendier, J.-F. Lontie, C. Delcroix, D.Y. Dubois, T. Magot, and L. de Roy Apolipoproteins C-II and C-II I metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration Atherosclerosis 77 1989 139 149
36. R. Batal, M. Tremblay, and P.H. Barrett Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects J. Lipid Res. 41 2000 706 718
37. J.S. Cohn, B.W. Patterson, K.D. Uffelman, J. Davignon, and G. Steiner Rate of production of plasma and VLDL apoC-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity J. Clin. Endo. Metab. 89 2004 3949 3955
38. R.W. Mahley, and S.C. Rall Jr. Type III hyperlipoproteinemia (dysbeta-lipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism C.R. Scriver A.L. Beaudet W.S. Sly D. Valle The metabolic basis of inherited disease 1989 McGraw-Hill New York 1195 1213
39. J.S. Cohn, M. Tremblay, and R. Batal Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia J. Lipid Res. 43 2002 1464 1471
40. J.S. Cohn, D.A. Wagner, S.D. Cohn, J.S. Millar, and E.J. Schaefer Measurement of very low density and low density lipoprotein apolipoprotein (apo) B-100 and high density lipoprotein apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding J. Clin. Invest. 85 1990 804 811
41. R. Batal, M. Tremblay, and M. Krimbou Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I Arterioscler. Thromb. Vasc. Biol. 18 1998 655 664
42. J.S. Cohn, M. Tremblay, and M. Amiot Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects Arterioscler. Thromb. Vasc. Biol. 16 1996 149 159
43. S. Rahimkhani, K. Tran, Y. Wang, and Z. Yao Level of apoC-III mRNA correlates positively to the secretion of triglyceride-rich VLDL from transfected McA-RH7777 cells Circulation 102 II-148 2000 [abstract]
44. D.H. Blankenhorn, P. Alaupovic, E. Wickham, H.P. Chin, and S.P. Azen Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors Circulation 81 1990 470 476
45. H.N. Hodis, W.J. Mack, and S.P. Azen Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin Circulation 90 1994 42 49
46. E. Koren, C. Corder, and G. Mueller Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease Atherosclerosis 122 1996 105 115
47. F.M. Sacks, P. Alaupovic, and L.A. Moye VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial Circulation 102 2000 1886 1892
48. S.J. Lee, H. Campos, L.A. Moye, and F.M. Sacks LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients Arterioscler. Thromb. Vasc. Biol. 23 2003 853 858
49. B. Staels, N. Vu-Dac, and V.A. Kosykh Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates J. Clin. Invest. 95 1995 705 712
50. S. Haubenwallner, A.D. Essenburg, and B.C. Barnett Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action J. Lipid Res. 36 1995 2541 2551